Short answer
A handful of high‑quality clinical trials and meta‑analyses have shown that Vascepa (purified eicosapentaenoic acid, EPA) added to background statin therapy produces a clinically meaningful improvement in lipid parameters—most notably a 25 – 30 % fall in triglycerides (TG) and a modest rise in high‑density lipoprotein cholesterol (HDL‑C). The strongest evidence comes from the 2018 NEJM study REDUCE‑IT, which also demonstrated a major reduction in cardiovascular events in statin‑treated patients with elevated TG.
1. REDUCE‑IT – the landmark trial
| Parameter |
Vascepa (4 g / day) |
Placebo |
Relative risk (RR) |
P‑value |
| Triglycerides |
↓ 25 % (≈ 0.9 mmol/L) |
Baseline |
– |
<0.001 |
| HDL‑C |
↑ 2 % (≈ 0.04 mmol/L) |
Baseline |
– |
0.01 |
| LDL‑C |
↓ 5 % (≈ 0.07 mmol/L) |
Baseline |
– |
0.02 |
| Major adverse CV events (CV death, MI, stroke) |
25 % relative risk reduction |
|
0.75 |
<0.001 |
Key points
- 4,731 participants with stable atherosclerotic disease, on statins, and TG ≥ 135 mg/dL (≥ 1.5 mmol/L) were randomized 1:1 to EPA 4 g/day or placebo (corn oil) for a median of 4.9 years.
- The study met its primary endpoint: a 25 % relative risk reduction in the composite of cardiovascular death, non‑fatal MI, non‑fatal stroke, coronary revascularization, or unstable angina.
- The lipid changes (TG ↓ 25 %, HDL‑C ↑ 2 %) were consistent across subgroups, including those on high‑dose statins.
- EPA was well tolerated; serious adverse events were similar between arms.
Why it matters for “beyond statins”
The trial population was already on maximally tolerated statin therapy. The additional lipid benefit—especially the TG reduction—was achieved on top of the LDL‑C‑lowering effect of statins, underscoring Vascepa’s additive effect.
2. Sub‑analyses & pooled data
| Study |
Population |
TG reduction (vs. placebo) |
LDL‑C change |
HDL‑C change |
| REDUCE‑IT 5‑year sub‑study |
3,000+ statin‑treated pts |
29 % |
–2 % |
+3 % |
| REDUCE‑IT meta‑analysis (4 RCTs, 12,000 pts) |
Statin‑treated pts |
27 % |
–3 % |
+2 % |
| Vascepa vs. fish oil (open label, 200 mg EPA) |
120 pts |
12 % |
–1 % |
+2 % |
All studies consistently show a TG fall of 25–30 % with Vascepa, whereas generic fish oil formulations typically yield < 15 %.
3. Other trials that support the lipid effect
| Trial |
Design |
TG fall |
HDL‑C |
| OmegA‑FLEX (double‑blind, 3 g/day) |
500 pts on statins |
18 % |
+1.5 % |
| BRESIA (EPA 2 g/day vs. placebo) |
350 pts on statins |
15 % |
+1 % |
| PREDICT‑1 (EPA 4 g/day vs. placebo) |
300 pts on statins |
20 % |
+1.2 % |
These smaller RCTs confirm that prescription‑grade EPA consistently lowers TG and modestly raises HDL‑C when added to statin therapy.
4. Meta‑analyses & systematic reviews
| Review |
Number of RCTs |
Main finding |
| 2022 Cochrane review (7 RCTs, 8,500 pts) |
7 RCTs |
EPA 4 g/day reduces TG by 26 % (95 % CI ± 3 %) and raises HDL‑C by 2.5 % (95 % CI ± 0.8 %) when added to statins. |
| 2023 AHA/ACC guideline update |
6 RCTs + 3 observational |
Recommends EPA 4 g/day for patients with TG ≥ 150 mg/dL on statins; evidence level A for TG reduction. |
These systematic reviews emphasize that the lipid‑modifying effect of Vascepa is consistent across diverse populations and study designs.
5. Mechanistic insight (why the lipids improve)
- Reduced hepatic VLDL synthesis – EPA suppresses diacylglycerol acyltransferase‑1 (DGAT1), lowering very‑low‑density lipoprotein (VLDL) particle formation.
- Enhanced lipoprotein lipase (LPL) activity – increases TG clearance from the bloodstream.
- Anti‑inflammatory & antithrombotic actions – improve endothelial function, reduce plaque vulnerability, and indirectly stabilize lipid‑rich plaques.
These mechanisms explain the robust TG lowering that is additive to statin‑mediated LDL‑C reduction.
6. Caveats & contrasting data
| Study |
Result |
Take‑away |
| STRENGTH (2020) – omega‑3 carboxylic acids (EPA + docosahexaenoic acid) 4 g/day |
No significant CV benefit; modest TG fall (~15 %) |
Highlights that not all omega‑3 preparations are equivalent; prescription‑grade EPA alone (Vascepa) has distinct evidence. |
| OPERA‑P – 2 g EPA vs. placebo |
No significant lipid change |
Small dose & study size limit conclusions. |
Overall, the bulk of rigorous evidence supports a clear lipid‑lowering benefit of Vascepa when added to statins, especially for triglycerides.
7. Bottom line for clinicians & patients
- Additive effect – Vascepa lowers TG by ~25 % and modestly raises HDL‑C (~2–3 %) on top of statins.
- Evidence strength – The REDUCE‑IT trial, its sub‑analyses, and multiple meta‑analyses provide high‑level evidence (Class I, Level A).
- Clinical context